Elderflower (Sambucus nigra flos) is one of the oldest European diaphoretic remedies for feverish colds. Commission E approves the flowers for common cold. The strongest modern clinical evidence is actually for elderberry (the fruit), not the flower, with a meta-analysis showing large effect sizes for reducing upper respiratory symptoms. Elderflower's traditional role as a diaphoretic ("sweat cure" herb) and its inclusion in the Sinupret combination product are its most important contemporary uses. Clinical trial data specifically for elderflower monotherapy is limited.

Eucalyptus oil and its principal monoterpene component 1,8-cineole are well-established in European phytotherapy for respiratory catarrh, bronchitis, sinusitis, and as adjunctive therapy in COPD and asthma. The isolated compound 1,8-cineole (available as Soledum capsules in Germany) has stronger and more specific clinical evidence than crude eucalyptus oil preparations. Multiple clinical trials demonstrate anti-inflammatory effects, mucolytic activity, and steroid-sparing potential. Commission E and ESCOP both approve eucalyptus oil for respiratory catarrh.

Iceland Moss (Cetraria islandica) is a lichen -- not a true moss -- with a long history in Nordic and Central European herbal medicine as a demulcent for dry coughs, sore throats, and upper respiratory irritation. Commission E approved it for loss of appetite and catarrhs of the upper respiratory tract, and EMA grants traditional use status for dry cough and oral/pharyngeal irritation as well as temporary appetite loss. The key active constituents are polysaccharides (lichenin, isolichenin) that form a soothing mucilaginous layer on irritated mucous membranes, along with bitter lichen acids (usnic acid, fumarprotocetraric acid) that stimulate appetite. Despite centuries of use in Scandinavian and Alpine folk medicine, virtually no modern clinical trial evidence exists. It remains a well-regarded traditional remedy in European pharmacy, particularly in cough lozenges and throat teas.

Ivy leaf extract is one of the best-evidenced herbal expectorants in European phytotherapy. The standardized extract EA 575 (marketed as Prospan) has been studied in over 65,000 patients across clinical and observational studies. It has a well-characterized molecular mechanism involving indirect beta-2 adrenergic receptor stimulation via the saponin alpha-hederin. It holds approvals from all three major European regulatory bodies (Commission E, ESCOP, EMA/HMPC) and is widely used in pediatric practice.

Linden flower (Tiliae flos) is one of the most traditional European remedies for feverish colds, used for centuries as a diaphoretic "sweat cure" herb. It has Commission E, ESCOP, and EMA/HMPC approval, but its evidence base is almost entirely from traditional use rather than clinical trials. No meaningful modern RCTs exist. Its diaphoretic mechanism is attributed to flavonoids (quercetin, kaempferol) and phenolic acids. It remains very popular as a home remedy tea in German-speaking countries. There is a notable safety concern: the German Commission E monograph mentions potential cardiotoxicity, though this is contested and may apply only to excessive doses.

Marshmallow root is one of the oldest and most respected demulcent herbs in European phytotherapy, specifically indicated for dry irritative cough and mucous membrane irritation. It holds Commission E, ESCOP, and EMA/HMPC approval. Its mechanism -- bio-adhesive mucilage polysaccharides forming a protective film on irritated mucosa -- is well-understood and pharmacologically elegant. Clinical evidence includes a large consumer survey (n=822) demonstrating rapid symptom relief, but large placebo-controlled RCTs are lacking. The standardized extract STW 42 (Phytohustil) is the most studied preparation.

Mullein flower (Verbasci flos) is a traditional European demulcent and expectorant herb used for centuries in the treatment of respiratory catarrh and cough. It holds Commission E approval for catarrhs of the respiratory tract and EMA traditional use registration as an expectorant in cough associated with cold, but is not covered by ESCOP. Its mucilage content (approximately 3%) provides a soothing demulcent effect on irritated mucous membranes, while saponins (verbascosaponin) contribute a mild expectorant action. Clinical trial evidence is essentially absent; approval rests almost entirely on longstanding traditional use and pharmacological plausibility. Mullein is frequently used in combination with other respiratory herbs such as thyme and marshmallow in European herbal tea blends.

Myrtol standardized (ELOM-080, marketed as GeloMyrtol forte) is a unique phytopharmaceutical consisting of a defined essential oil distillate with standardized content of three monoterpenes: 1,8-cineole, d-limonene, and alpha-pinene. It has strong RCT evidence for both acute sinusitis and acute bronchitis, with a landmark trial showing efficacy comparable to the antibiotic cefuroxime and the mucolytic ambroxol. It is one of the best-selling OTC respiratory medicines in Germany. Its multi-target mechanism includes secretolytic, mucolytic, anti-inflammatory, antimicrobial, and bronchospasmolytic effects.

Ribwort plantain (Plantago lanceolata) is a traditionally important European respiratory herb approved by Commission E and ESCOP for catarrh of the airways and oral/throat mucosal inflammation. Its dual mechanism -- mucilage-based soothing of irritated membranes and iridoid glycoside-mediated anti-inflammatory action -- is well-supported by in vitro and preclinical evidence. However, robust clinical trial data is limited. It is primarily recommended for moderate chronic irritative cough, especially in children, where its excellent safety profile is advantageous. The EMA/HMPC classifies it under traditional use.

Primula veris (cowslip) is a key ingredient in two of Germany's most successful phytopharmaceuticals: Sinupret (for sinusitis) and Bronchipret (for bronchitis, in combination with thyme). As a single herb, it has Commission E and ESCOP approval for productive cough and bronchitis. The strongest clinical evidence is for the 5-herb combination Sinupret (BNO 1016), which has RCT evidence demonstrating efficacy in acute rhinosinusitis (healing rate 48.4% vs. 35.8% placebo). Sinupret is the only herbal product for rhinosinusitis with evidence from well-designed, adequately powered RCTs.

Thyme is one of the most widely approved and traditionally used respiratory herbs in European phytotherapy. It holds Commission E, ESCOP, and EMA/HMPC approvals for bronchitis and upper respiratory catarrh. Its best clinical evidence comes from combination products with primrose root (Bronchipret) rather than as monotherapy. A pivotal Phase IV trial (n=361) demonstrated that thyme-primrose combination reduced coughing fits 2 days faster than placebo. Thyme is considered very safe with essentially no reported adverse effects at therapeutic doses.

Vervain (Verbena officinalis) is a classic European folk medicine herb with a long history of use as a mild expectorant and anti-inflammatory. It holds EMA traditional use status for cough associated with colds and for mild menstrual pain, but lacks Commission E or ESCOP monographs. As monotherapy, there are no published RCTs. Its most significant modern clinical role is as a component of Sinupret (BNO 1016), the 5-herb combination product for acute rhinosinusitis, where it contributes anti-inflammatory and secretolytic properties alongside gentian root, elderflower, primrose, and sorrel. The iridoid glycosides verbenalin and hastatoside, along with the phenylethanoid verbascoside, are considered the primary active constituents. Evidence rating is minimal (E) for monotherapy.